<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurotherapeutics</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurotherapeutics</journal-id>
<journal-title-group>
<journal-title>Neurotherapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1933-7213</issn>
<issn pub-type="epub">1878-7479</issn>
<publisher>
<publisher-name>Springer US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28707277</article-id>
<article-id pub-id-type="pmc">5722761</article-id>
<article-id pub-id-type="publisher-id">555</article-id>
<article-id pub-id-type="doi">10.1007/s13311-017-0555-6</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>J. Y.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trivedi</surname>
<given-names>A. M.</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carrillo</surname>
<given-names>N. R.</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schneider</surname>
<given-names>A.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giulivi</surname>
<given-names>C.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Adams</surname>
<given-names>P.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tassone</surname>
<given-names>F.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>K.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rivera</surname>
<given-names>S. M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lubarr</surname>
<given-names>N.</given-names>
</name>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>C.-Y.</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Irwin</surname>
<given-names>R. W.</given-names>
</name>
<xref ref-type="aff" rid="Aff12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brinton</surname>
<given-names>R. D.</given-names>
</name>
<xref ref-type="aff" rid="Aff12">12</xref>
<xref ref-type="aff" rid="Aff13">13</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Olichney</surname>
<given-names>J. M.</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rogawski</surname>
<given-names>M. A.</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff14">14</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hagerman</surname>
<given-names>R. J.</given-names>
</name>
<address>
<email>rjhagerman@ucdavis.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0413 7653</institution-id><institution-id institution-id-type="GRID">grid.416958.7</institution-id><institution>UC Davis MIND Institute, </institution><institution>UC Davis Health, </institution></institution-wrap>Sacramento, CA USA </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>Department of Biochemistry and Molecular Medicine, School of Medicine, </institution><institution>University of California, Davis, </institution></institution-wrap>Sacramento, CA USA </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>School of Medicine, </institution><institution>University of California, Davis, </institution></institution-wrap>Sacramento, CA USA </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>Department of Neurology, School of Medicine, </institution><institution>University of California, Davis, </institution></institution-wrap>Sacramento, CA USA </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>Center for Mind and Brain, </institution><institution>University of California, Davis, </institution></institution-wrap>Davis, CA USA </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>Department of Pediatrics, School of Medicine, </institution><institution>University of California, Davis, </institution></institution-wrap>Sacramento, CA USA </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>Department of Molecular Biosciences, </institution><institution>University of California Davis, School of Veterinary Medicine, </institution></institution-wrap>Davis, CA USA </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>Department of Public Health Sciences, </institution><institution>University of California, Davis, </institution></institution-wrap>Davis, CA USA </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>Department of Psychology, </institution><institution>University of California Davis, </institution></institution-wrap>Davis, CA USA </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0423</institution-id><institution-id institution-id-type="GRID">grid.471368.f</institution-id><institution>Department of Neurology, </institution><institution>Mount Sinai Beth Israel Hospital, </institution></institution-wrap>New York, NY USA </aff>
<aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0413 7653</institution-id><institution-id institution-id-type="GRID">grid.416958.7</institution-id><institution>PK/PD Bioanalytical Core Facility, </institution><institution>UC Davis Health, </institution></institution-wrap>Sacramento, CA USA </aff>
<aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2156 6853</institution-id><institution-id institution-id-type="GRID">grid.42505.36</institution-id><institution>Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, </institution><institution>University of Southern California, </institution></institution-wrap>Los Angeles, CA USA </aff>
<aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2168 186X</institution-id><institution-id institution-id-type="GRID">grid.134563.6</institution-id><institution>Center for Innovation in Brain Science, School of Medicine, Departments of Pharmacology and Neurology, </institution><institution>University of Arizona, </institution></institution-wrap>Tucson, AZ USA </aff>
<aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>Department of Pharmacology, School of Medicine, </institution><institution>University of California, Davis, </institution></institution-wrap>Sacramento, CA USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>13</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2017</year>
</pub-date>
<volume>14</volume>
<issue>4</issue>
<fpage>1073</fpage>
<lpage>1083</lpage>
<permissions>
<copyright-statement>© The American Society for Experimental NeuroTherapeutics, Inc. 2017</copyright-statement>
</permissions>
<abstract id="Abs1">
<p id="Par1">Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder affecting approximately 45% of male and 16% of female carriers of the <italic>FMR1</italic> premutation over the age of 50 years. Currently, no effective treatment is available. We performed an open-label intervention study to assess whether allopregnanolone, a neurosteroid promoting regeneration and repair, can improve clinical symptoms, brain activity, and magnetic resonance imaging (MRI) measurements in patients with FXTAS. Six patients underwent weekly intravenous infusions of allopregnanolone (2–6 mg over 30 min) for 12 weeks. All patients completed baseline and follow-up studies, though MRI scans were not collected from 1 patient because of MRI contraindications. The MRI scans from previous visits, along with scans from 8 age-matched male controls, were also included to establish patients’ baseline condition as a reference. Functional outcomes included quantitative measurements of tremor and ataxia and neuropsychological evaluations. Brain activity consisted of event-related potential N400 word repetition effect during a semantic memory processing task. Structural MRI outcomes comprised volumes of the hippocampus, amygdala, and fluid-attenuated inversion recovery hyperintensities, and microstructural integrity of the corpus callosum. The results of the study showed that allopregnanolone infusions were well tolerated in all subjects. Before treatment, the patients disclosed impairment in executive function, verbal fluency and learning, and progressive deterioration of all MRI measurements. After treatment, the patients demonstrated improvement in executive functioning, episodic memory and learning, and increased N400 repetition effect amplitude. Although MRI changes were not significant as a group, both improved and deteriorated MRI measurements occurred in individual patients in contrast to uniform deterioration before the treatment. Significant correlations between baseline MRI measurements and changes in neuropsychological test scores indicated the effects of allopregnanolone on improving executive function, learning, and memory for patients with relatively preserved hippocampus and corpus callosum, while reducing psychological symptoms for patients with small hippocampi and amygdalae. The findings show the promise of allopregnanolone in improving cognitive functioning in patients with FXTAS and in partially alleviating some aspects of neurodegeneration. Further studies are needed to verify the efficacy of allopregnanolone for treating FXTAS.</p>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (doi:10.1007/s13311-017-0555-6) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Fragile X premutation</kwd>
<kwd>
<italic>FMR1</italic>
</kwd>
<kwd>Neurodegeneration</kwd>
<kwd>Allopregnanolone</kwd>
<kwd>FXTAS</kwd>
<kwd>Neurogenesis</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000071</institution-id>
<institution>National Institute of Child Health and Human Development</institution>
</institution-wrap>
</funding-source>
<award-id>U54 HD079125</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>Office of the Assistant Secretary of Defense for Health Affairs (US)</institution>
</funding-source>
<award-id>W81XWH-09-1-0746</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id>
<institution>National Institute on Aging</institution>
</institution-wrap>
</funding-source>
<award-id>R01 AG04825</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>Private donations</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The American Society for Experimental NeuroTherapeutics, Inc. 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>